Zajaczkowska Małgorzata, Stefaniak Jolanta, Sikora Przemysław, Choma-Smaga Marta, Filiks-Litwin Barbara, Szajner-Milart Irena, Borzecka Halina
Department of Pediatric Nephrology, Medical University of Lublin.
Ann Univ Mariae Curie Sklodowska Med. 2003;58(1):348-53.
The purpose of the study was to estimate the urinary excretion of NAG and alpha-1M among children who suffer from proliferative blood diseases. The group of the examined children included those who went through a viral hepatitis (VH) and who are or were treated by means of cytostatic drugs. The study comprised 73 children aged from 4 to 18 (average 11.7+/-3.5. There were 70 children with the diagnosis of leukemia and 3 with the diagnosis of non-Hodgkin lymphoma. The examined group was divided according to the stage of treatment of a basic disease. Group I--22 children who are treated currently or whose treatment has been completed recently. Group II--51 children whose treatment was completed over two years ago. In group II there were 4 subgroups distinguished depending on positive antigenemia HBs and the presence of HCV antibodies. There were no clinical or biochemical features of damage of renal function observed among any of the children. The testing group consisted of 70 healthy children who were selected regarding age and sex. The urinary excretion of NAG and alpha-1M was estimated in the second morning portion of urine and it was presented as NAG/creatinine and alpha-1M/creatinine ratio. The results of the research underwent the statistical analysis by means of a t-Student test. It was stated that the urinary excretion of NAG and alpha-1M was higher among children who currently are or were treated by means of cytostatics drugs. It was also stated that the urinary excretion of NAG was higher among the children who went through viral hepatitis C in comparison with HBs antigen carriers. Similarly, the urinary excretion of alpha-1M was higher among children with positive markers of viral hepatitis B and C markers in comparison with a group of HBs antigen carriers.
本研究的目的是评估患有增殖性血液疾病的儿童中N-乙酰-β-D-氨基葡萄糖苷酶（NAG）和α1-微球蛋白（α-1M）的尿排泄情况。被检查儿童组包括患有病毒性肝炎（VH）以及正在或曾经接受细胞毒性药物治疗的儿童。该研究纳入了73名年龄在4至18岁之间的儿童（平均年龄11.7±3.5岁）。其中70名儿童被诊断为白血病，3名儿童被诊断为非霍奇金淋巴瘤。根据基础疾病的治疗阶段对被检查组进行划分。第一组——22名正在接受治疗或近期已完成治疗的儿童。第二组——51名治疗已结束超过两年的儿童。在第二组中，根据乙肝表面抗原血症阳性和丙肝抗体的存在情况区分出4个亚组。所有儿童均未观察到肾功能损害的临床或生化特征。测试组由70名根据年龄和性别挑选出的健康儿童组成。在晨尿的第二部分中评估NAG和α-1M的尿排泄情况，并以NAG/肌酐和α-1M/肌酐比值表示。研究结果通过t检验进行统计分析。结果表明，目前正在或曾经接受细胞毒性药物治疗的儿童中，NAG和α-1M的尿排泄量较高。还表明，与乙肝表面抗原携带者相比，患有丙型病毒性肝炎的儿童中NAG的尿排泄量较高。同样，与乙肝表面抗原携带者组相比，乙肝和丙肝病毒标志物呈阳性的儿童中α-1M的尿排泄量较高。
